- Global Pharma News & Resources

Market Analysis for Global Alzheimer’s Disease Diagnostic Market by Type, Applications, Regions and Forecast 2020 – 2025

Alzheimer’s Disease Diagnostic Market was valued at USD 3.01 Billion in 2020 and is projected to reach USD 5.23 Billion by 2025, growing at a CAGR of 7.30% from 2020 to 2025.

Alzheimer's disease (AD) is the most common cause of progressive dementia in the elderly population. This is a neurodegenerative, progressive, irreversible disorder caused by abnormal functioning of brain cells, namely the failure of synaptic transmission, leading to loss of cognitive function. In this condition, the patient has abnormal brain functions that affect memory, language, thinking, judgment, and behavior.

Memory loss, insomnia, repetitive movements, agitation, anxiety, depression, and loss of reasoning abilities are some of the signs and symptoms of Alzheimer’s disease. The stages of this disease typically progress from mild to moderate to severe. There is no single diagnostic test that can determine if the person has Alzheimer’s disease. Physicians (often with the help of specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists) use a variety of approaches and tools in order to help make a diagnosis.

Get sample copy of this report here:


Global Alzheimer’s Disease Diagnostic Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;


By Type, Alzheimer’s Disease Diagnostic has been segmented into:          

  • Nervous System Examination
  • Genetic Testing
  • Minor Mental State Examination
  • Brain Imaging


By Application, Alzheimer’s Disease Diagnostic has been segmented into:

  • Early-Onset Alzheimer's Disease
  • Familial Alzheimer's Disease
  • Late-Onset Alzheimer's Disease


Regions and Countries Level Analysis:         

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
  • Asia-Pacific (China, India, Japan, Southeast Asia etc.)
  • South America (Brazil, Argentina etc.)
  • Middle East & Africa (Saudi Arabia, South Africa etc.)


The diagnosis of Alzheimer's disease includes a complete assessment of all possible causes, from medical history to brain examination. Laboratory and imaging tests can rule out other potential causes or help doctors ineffectively characterize the symptoms of dementia that cause the disease. PET scans are one of those tools that can detect tau, an abnormal protein, another characteristic of Alzheimer's dementia. Diagnostic close-up tests include physical and neurological tests, laboratory tests, neuropsychological tests, mental status, and brain imaging tests. Additionally, scientists are investigating many disease markers and diagnostic tests such as genes, disease-related proteins, and imaging procedures. This investigation can accurately and reliably indicate whether a person has Alzheimer's dementia and how far the disease has progressed.

Alzheimer’s Disease Diagnostic Market report covers global and regional market analysis. The report examines the records and presents the global market size of important players in each region of the world. The report also provides information on the market leaders. It consists of important global market shares, size and trends such as product profit, price, value and capacity, supply and demand, and industry growth rate.

Editor Details

Last Updated: 09-Feb-2021